Nuvo Research completes WF10 Phase 2 trial in patients with refractory allergic rhinitis

- Top-Line Results Expected in February 2015 -

Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of immunology and topical products, today announced that 179 patients have completed its 16-week, double-blind, placebo-controlled, Phase 2 clinical trial to investigate the safety and efficacy of WF10 in patients with refractory allergic rhinitis. The Company expects to release the top-line results of the study in mid-February of 2015.

"We are excited to have completed the 16-week patient treatment and monitoring phase of the study and we expect to release top-line results in mid-February 2015," said Dr. Henrich Guntermann, President, Europe & Immunology Group. "One of the main purposes of the study is to validate the results of our 60-patient Phase 2 proof-of-concept study conducted in 2010. Patients in that study and in independent case studies have reported that a single 5-day course of treatment with WF10 could provide 1 to 2 years of symptomatic relief from multiple air-borne allergens. These unique attributes make WF10 a revolutionary product candidate for patients who don't obtain adequate relief from standard allergy treatments such as antihistamines and inhaled corticosteroids."